Search results
Results From The WOW.Com Content Network
Cancers is a peer-reviewed, open access, medical journal published by MDPI covering all fields of oncology. [1] The editor-in-chief is Samuel C. Mok (The University of Texas MD Anderson Cancer Center). The Irish Association for Cancer Research (IACR) and the Signal Transduction Society (STS) are affiliated societies.
Cancer is a biweekly peer-reviewed scientific journal covering oncology. The journal was established in 1948. It is an official journal of the American Cancer Society and is published by Wiley-Blackwell on behalf of the society. The first editor-in-chief was Fred W. Stewart, who held that position until 1961.
The editors-in-chief are Vincent T. DeVita (Yale Cancer Center), Theodore S. Lawrence (University of Michigan), and Steven Rosenberg (National Cancer Institute). According to the Journal Citation Reports, the journal has a 2022 impact factor of 2.2, ranking it 199th out of 241 journals in the category "Oncology". [1]
The Journal of the National Comprehensive Cancer Network, established in 2003, is a monthly peer-reviewed medical journal of oncology and the official journal of the National Comprehensive Cancer Network (NCCN). It is published by Harborside Press and the editor-in-chief is Margaret Tempero (UCSF Helen Diller Family Comprehensive Cancer Center ...
CA: A Cancer Journal for Clinicians is a bimonthly peer-reviewed medical journal published for the American Cancer Society by Wiley-Blackwell. The journal was established in 1950 and covers aspects of cancer research on diagnosis , therapy , and prevention . [ 1 ]
Innovative oncology, up 11%, seven oncology products we have in 2024. We think that's a very strong portfolio to help patients with oncology and hematology disease. Rare disease, up to about $4.5 ...
It covers research on all aspects of cancer and cancer-related biomedical sciences and was established in 1941. The editor-in-chief is Chi Van Dang. [1] The journal was established in 1916 as the Journal of Cancer Research, was renamed American Journal of Cancer in 1931, and obtained its current name in 1941.
In oncology, we expect global sales of $6.3 billion including IMBRUVICA revenue of $2.7 billion which reflects a $400 million net unfavorable impact from the Medicare Part D benefit redesign ...